BioNTech SE

BNTXintermediary

BioNTech is a German biotechnology company that co-developed the first authorized mRNA COVID-19 vaccine with Pfizer. It is now leveraging its mRNA platform for individualized cancer vaccines, infectious disease programs, and cell therapies.

⇄ Compare

Productos e Ingresos

Participación de Ingresos por Producto

Desglose de Ingresos ($4.8B)

Datos estáticos (cargando finanzas en tiempo real…)

COVID-19 Vaccine Revenue (68%)

Collaboration Revenue (Pfizer) (18%)

R&D Grants & Other (14%)

Composición de segmentos y clientes principales

Detalles del producto

Comirnaty (COVID-19 Vaccine)55%

mRNA-based COVID-19 vaccine developed with Pfizer

Oncology mRNA (BNT111, BNT122)15%

Individualized mRNA cancer vaccines targeting solid tumors

Infectious Disease Pipeline10%

mRNA vaccines for influenza, shingles, and malaria

Relaciones en la Cadena de Suministro

Socios

Pfizer Inc.

Comirnaty COVID vaccine co-development

Impacto: Critical — Pfizer is primary commercialization partner

Competidores

Moderna, Inc.

mRNA vaccines and oncology

Impacto: Primary mRNA competitor

Regeneron Pharmaceuticals

Cancer immunotherapy

Impacto: Competing in oncology

Contexto macro y de mercado

제약 / 바이오Noticias del sector

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Próximos catalizadores

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Últimas noticias

Cargando noticias...

Análisis IA

Haz clic en "Obtener Análisis IA" para un análisis de cadena de suministro de BioNTech SE impulsado por IA.

Información de la Empresa

Sede Central

Mainz, Germany

Fundación

2008

Empleados

6,000+

Sitio Web

biontech.com

Estado del sector — 제약 / 바이오

Noticias del sector